Leukemia is a type of cancer that affects the blood and bone marrow, where blood cells are formed. All types of leukemia cause rapid, uncontrolled growth of abnormal bone marrow and blood cells.
The main differences between the types include how fast the disease progresses and the types of cells it affects.
There are four main types of leukemia, which we describe in detail below:
Lymphocytic leukemia affects the lymphocytes, a type of white blood cell. Myeloid leukemia can affect the white blood cells, red blood cells, and platelets.
According to the National Cancer Institute, roughly 1.5% of people in the United States will receive a leukemia diagnosis at some point.
In this article, explore the four main types, their symptoms, the treatment options available, and the outlook.
The full name of this type of cancer is acute lymphocytic leukemia, and acute means that it grows quickly. Lymphocytic means that it forms in underdeveloped white blood cells called lymphocytes.
The disease starts in the bone marrow, which produces stem cells that develop into red and white blood cells and platelets.
In a healthy person, the bone marrow does not release these cells until they are fully developed. In someone with ALL, the bone marrow releases large quantities of underdeveloped white blood cells.
There are several subtypes of ALL, and the subtype may influence the best course of treatment and the prognosis.
One subtype is B-cell ALL. This begins in the B lymphocytes, and it is the most common form of ALL in children.
Another subtype is T-cell ALL. It can cause the thymus, a small organ at the front of the windpipe, to become enlarged, which can lead to breathing difficulties.
Overall, because ALL progresses quickly, swift medical intervention is key.
As research from 2020 acknowledges, healthcare providers still do not know what causes ALL. It may occur due to genetic factors or exposure to:
Although genetic factors may play a role, ALL is not a familial disease.
Learn more about ALL here.
ALL is the most common form of leukemia in children.
The risk of developing it is highest in children under 5 years old. The prevalence slowly rises again in adults over 50.
ALL symptoms can be nonspecific difficult to distinguish from those of other illnesses.
They may include:
In a person with AML, the bone marrow makes abnormal versions of platelets, red blood cells, and white blood cells called myeloblasts.
The full name of this disease is acute myeloid leukemia, and acute refers to the fact that it is fast-growing.
It forms in one of the following types of bone marrow cell:
Doctors classify AML by subtype, depending on:
AML can be difficult to treat and requires prompt medical attention.
Learn more about AML here.
The most common risk factor is myelodysplastic syndrome, a form of blood cancer that keeps the body from producing enough healthy blood cells.
Other factors that increase the risk of developing AML include:
Most people who develop AML are over 45. It is one of the most common types of leukemia in adults, though it is still rare, compared with other cancers.
It is also the second most common form of leukemia in children.
Symptoms of AML can vary and may include:
CLL is the most common form of leukemia among adults in the U.S. and other Western countries.
There are two types. One progresses slowly, and it causes the body to have high levels of characteristic lymphocytes, but only slightly low levels of healthy red blood cells, platelets, and neutrophils.
The other type progresses more quickly and causes a significant reduction in levels of all healthy blood cells.
In someone with CLL, the lymphocytes often look fully formed but are less able to fight infection than healthy white blood cells. The lymphocytes tend to build up very slowly, so a person might have CLL for a long time before experiencing symptoms.
Learn more about CLL here.
Genetic factors are the most likely cause. Others might include:
CLL is rare in children. It typically develops in adults aged 70 or over. However, it can affect people as young as 30.
CLL typically causes no early symptoms. When symptoms are present, they may include:
Also, 5090% of people with CLL have swollen lymph nodes.
CML is a slow-growing type of leukemia that develops in the bone marrow.
The full name of CML is chronic myeloid leukemia. As the American Cancer Society explain, a genetic change takes place in the early forms of the myeloid cells, and this eventually results in CML cells.
These leukemia cells then grow, divide, and enter the blood.
CML occurs due to a rearrangement of genetic material between the chromosomes 9 and 22.
This rearrangement fuses a part of the ABL1 gene from chromosome 9 with the BCR gene from chromosome 22, called the Philadelphia chromosome. The result of this fusion is called BCR-ABL1.
BCR-ABL1 produces a protein that promotes cell division and stops apoptosis, the process of cell death, which typically removes unneeded or damaged cells.
The cells keep dividing and do not self-destruct, resulting in an overproduction of abnormal cells and a lack of healthy blood cells.
This occurs during the persons lifetime and is not inherited.
CML typically affects adults. People aged 65 and older make up almost half of those who receive a CML diagnosis.
The symptoms of CML are unclear, but they may include:
The symptoms may vary, depending on the type of leukemia. Overall, a person should get in touch with a doctor if they experience:
Learn more about the symptoms of leukemia here.
Treatment for ALL typically involves three basic phases: induction, consolidation, and maintenance. We describe these in detail below.
Treatment for AML involves the first two phases. The induction phase may include treatment with the chemotherapy drugs cytarabine (Cytosar-U) and daunorubicin (Cerubidine) or idarubicin (Idamycin). The doctor may also recommend targeted drugs.
The goal of this phase is to kill the leukemia cells, causing the cancer to go into remission, using chemotherapy.
The doctor may recommend:
People having chemotherapy may need to see their doctors frequently and spend time in the hospital, due to the risk of serious infections and complications.
This phase of the treatment lasts for about 1 month.
Even if the treatment so far has led to remission, cancer cells may be hiding in the body, so more treatment is necessary.
The consolidation phase may involve taking high doses of chemotherapy. A doctor may also recommend targeted drugs or stem cell transplants.
This phase, consisting of ongoing chemotherapy treatments, usually lasts for 2 years.
Since CLL tends to progress slowly, and its treatment can have unpleasant side effects, some people with this condition go through a phase of watchful waiting before starting the treatment.
For a person with CML, the focus is often on providing the right treatment for the phase of the illness. To do this, a doctor considers how quickly the leukemia cells are building up and the extent of the symptoms. Stem cell transplants can be effective, but further treatment is necessary.
Overall, the initial treatment tends to include monoclonal antibodies, targeted drugs, and chemotherapy.
If the only concern is an enlarged spleen or swollen lymph nodes, the person may receive radiation or surgery.
If there are high numbers of CLL cells, the doctor may suggest leukapheresis, a treatment that lowers the persons blood count. This is only effective for a short time, but it allows the chemotherapy to start working.
For people with high-risk disease, doctors may recommend stem cell transplants.
A persons prognosis depends on the type of leukemia.
Learn more about survival rates for people with leukemia here.
About 8090% of adults with ALL experience complete remission for a while during treatment. And with treatment, most children recover from the disease.
Relapses are common in adults, so the overall cure rate is 40%. However, factors specific to each person play a role.
The older a person is when they receive an AML diagnosis, the more difficult it is to treat.
More than 25% of adults who achieve remission live for 3 years or more after treatment for AML.
A person may live for a long time with CLL.
Treatments can help keep the symptoms under control and prevent the disease from spreading. However, there is no cure.
Stem cell transplants can cure CML. However, this treatment is very invasive and is not suitable for most people with CML.
The United Kingdoms National Health Service estimate that 70% of males and 75% of females live for at least 5 years after receiving a CML diagnosis.
The earlier a person receives the diagnosis, the better their outlook.
Leukemia is a type of cancer that affects the blood and bone marrow. It can affect people of all ages.
There are four main types of leukemia. They differ based on how quickly they progress and the types of cells they affect.
Treatments for all types of leukemia continue to improve, helping people live longer and more fully with this condition.
Read more from the original source:
Types of leukemia: Prevalence, treatment options, and prognosis - Medical News Today
- UC Irvine Study Reveals Risks Associated with Direct-to-Consumer Ads for Stem Cell and Exosome COVID-19 Therapies - India Education Diary - November 18th, 2023
- STEM | Description, Development, & Facts | Britannica - January 31st, 2023
- What is STEM Education? | Live Science - January 31st, 2023
- Science, Technology, Engineering, and Math, including Computer Science - ed - January 23rd, 2023
- What Does STEM Stand For? Definition, Degrees and More - January 23rd, 2023
- What Is STEM? - Definition & Resources for Teachers - January 23rd, 2023
- Science, technology, engineering, and mathematics - Wikipedia - January 23rd, 2023
- Stem Definition & Meaning - Merriam-Webster - January 23rd, 2023
- November: labblood-study | News and features - University of Bristol - November 7th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 7th, 2022
- Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and... - November 7th, 2022
- Type 2 Diabetes Stem Cell Therapy - Top U.S. Stem Cell ... - January 1st, 2022
- Cancer Drug Approvals from 2021 That Patients May Have Missed - Curetoday.com - January 1st, 2022
- Late effects in survivors of high-risk neuroblastoma following stem cell transplant with and without total body irradiation - DocWire News - January 1st, 2022
- The new life of a teenager with a strange tumor on his face after the operation - Market Research Telecast - January 1st, 2022
- Best of what was new in diabetes health for 2021 - Dickson Post - January 1st, 2022
- Hematopoietic Stem Cell Transplantation - StatPearls ... - December 22nd, 2021
- Autologous Stem Cell Transplant for Multiple Myeloma - December 22nd, 2021
- City of Hope presents leading-edge research on blood cancer therapies and its vaccine to reduce stem cell transplant complications at American Society... - December 22nd, 2021
- Adaptation Is Key to Advancing Care for Adult Patients With Leukemia - OncLive - December 22nd, 2021
- FDA Approves First Drug to Prevent Graft Versus Host Disease | FDA - FDA.gov - December 22nd, 2021
- Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients - Yahoo Finance - December 22nd, 2021
- After throwing goodbye party, woman with cancer finds hope close to home in Austin - Austin American-Statesman - December 22nd, 2021
- Dr. K.M. Cherian Heart Foundation & Educational Society Organized Cme Programme & Workshop On Cell Culture And Regenerative Medicine - APN... - December 22nd, 2021
- Namesake of new center a young man in love with the pursuit of knowledge - The Saint Anselm Crier - November 7th, 2021
- Red Cross blood drive focuses on sickle cell disease fight - Palladium-Item - November 7th, 2021
- Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries - KULR-TV - November 7th, 2021
- 1st CRISPR Gene Editing Trial Slated to Open in Severe SCD Patients - Sickle Cell Anemia News - April 4th, 2021
- Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network - April 4th, 2021
- Timely Bone Marrow Transplant by Fortis gives new lease of life to a patient with Multiple Myeloma - APN News - April 4th, 2021
- Kirron Kher is suffering with Multiple Myeloma: Know the causes, symptoms and more about this type of blood cancer - Jagran English - April 4th, 2021
- Decitabine Improved Outcomes for Patients With Refractory Prolonged Isolated Thrombocytopenia - Hematology Advisor - April 4th, 2021
- Lake in the Hills police officer and father of 4 kids battling rare cancer forced to retire - Lake and McHenry County Scanner - April 4th, 2021
- Insulin 100: How the road to a diabetes cure is yielding better treatments - News@UofT - April 4th, 2021
- Boxcar Scars Market |Exclusive Report on Latest Trends and Market Growth Opportunities - BioSpace - April 4th, 2021
- Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult... - April 4th, 2021
- BeyondSpring Announces Submission of New Drug Application to US FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of... - April 4th, 2021
- Roche receives first FDA clearance for urine sample type for BK virus quantitative test to aid in the improvement of care for transplant patients -... - February 14th, 2021
- Energy drinks may damage the heart, researchers warnshould the FDA get involved? - Cardiovascular Business - February 14th, 2021
- FDA Approves G1 Therapeutics' COSELA (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced... - February 14th, 2021
- Easter Ross mum of blood cancer tot urges would-be stem cell donors to show the love this Valentine's Day; Alness lass Adeline Davidson's plight... - February 14th, 2021
- Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas... - February 14th, 2021
- Leukemia in children: Symptoms, causes, treatment, outlook, and more - Medical News Today - February 7th, 2021
- After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now - February 7th, 2021
- Understanding bone marrow transplant: The guidelines and the protocols - The New Indian Express - February 4th, 2021
- Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia - February 4th, 2021
- Mobilize family caregivers to speed the rollout of Covid-19 vaccines - STAT - February 4th, 2021
- People With Cancer Should Receive COVID-19 Vaccine, Experts Say - Cancer Health Treatment News - February 4th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy f - PharmiWeb.com - February 4th, 2021
- APOE Tied to Increased Susceptibility to SARS-CoV-2 | ALZFORUM - Alzforum - February 4th, 2021
- Transforming Outcomes in Advanced CSCC with Immunotherapy - LWW Journals - February 4th, 2021
- Ashley Cain is living his worst nightmare as his baby daughter battles leukaemia in hospital - The Sun - February 4th, 2021
- Canada's blood supply has a diversity problem and people are dying because of it - CBC.ca - February 1st, 2021
- Autologous Stem Cell and Non Stem Based therapies Market Share, Size 2021 Global Industry Future Trends, Growth, Strategies,, Segmentation, In-depth... - February 1st, 2021
- Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical... - February 1st, 2021
- Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA... - February 1st, 2021
- Disabled People Are Waiting, Anxiously, For Lifesaving Covid-19 Vaccinations - Forbes - February 1st, 2021
- Family of Belfast woman Eimear Gooderham (25) share memories and dealing with grief in special UTV programme - Belfast Telegraph - February 1st, 2021
- Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation - Science Advances - February 1st, 2021
- The Need for New Biological Targets for Therapeutic Intervention in COPD - Pulmonology Advisor - February 1st, 2021
- What Patients With Cancer, Survivors Need to Know About the Emergency Use Authorization of COVID-19 Vaccine - Curetoday.com - December 19th, 2020
- Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On - Good News Network - December 19th, 2020
- Are Hiccups a Sign of the New Coronavirus? - Healthline - December 19th, 2020
- KEYTRUDA Plus LENVIMA Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective... - December 19th, 2020
- Covid-19 can have impact on heart too, say experts - Hindustan Times - December 19th, 2020
- Even if You've Had COVID-19 You Still Need the Vaccine - Healthline - December 19th, 2020
- The Link Between Cancer and Metabolic Dysfunction - Technology Networks - December 19th, 2020
- Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes -... - December 19th, 2020
- Gene therapy gives man with sickle cell disease the chance for a better future - Science Codex - December 3rd, 2020
- Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous... - December 3rd, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - December 3rd, 2020
- Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 - The Market Feed - December 3rd, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - India Education Diary - December 3rd, 2020
- Coinfection: more than the sum of its parts - Science Codex - November 19th, 2020
- Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to... - November 17th, 2020
- FDA Approves Merck's KEYTRUDA in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple?Negative Breast... - November 17th, 2020
- Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection - DocWire News - November 17th, 2020
- Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech - November 17th, 2020
- UH announces participation in clinical trial testing antibodies to treat COVID-19 in adults - News 5 Cleveland - November 7th, 2020
- Cord Blood Banking Market Technological Innovations And Future Opportunities 202 - Fractovia News - November 7th, 2020